Reckitt Benckiser Group plc (RBGPF)
NEUTRALFundamental
52
Preço
$5150.00
Capitalização de Mercado
$32.48B
Parte 1 · Quanto vale a empresa
Visão Geral
Reckitt Benckiser makes and sells branded household health and hygiene products: disinfectants and cleaners such as Lysol and Dettol, over-the-counter medicines such as Nurofen and Strepsils, condoms under Durex, and infant formula through its Mead Johnson Nutrition unit. It manufactures its own products and sells them through supermarkets, pharmacies and e-commerce worldwide. On 31 December 2025 it completed the sale of its Essential Home division (Air Wick, Calgon, Cillit Bang and about 75 other brands) to Advent International, keeping a 30% stake in the buyer.
Como gera receita
Revenue comes from selling packaged consumer goods through retailers, who buy at wholesale prices and mark them up for shelf sale. Margins depend on brand strength: a well-known name lets Reckitt charge more than an unbranded or store-label equivalent for a nearly identical product. Since January 2025 the group reports by geography — Core Emerging Markets, Core Europe, Core North America — plus Mead Johnson Nutrition as a separate line, after moving away from its former Health/Hygiene/Nutrition split.
Vantagem competitiva
Marca · EstreitaReckitt owns a portfolio of category-leading brands built over decades — Dettol in disinfection, Durex in condoms, Nurofen in pain relief — that let it command a premium over unbranded rivals. The advantage is narrow rather than wide: retailers' own store brands and generic pharmacy equivalents compete directly on price in most of these categories, and brand loyalty alone does not stop customers from trading down when budgets tighten.
O que impulsiona a procura
DefensivoMost of the portfolio — disinfectants, pain relief, feminine care — covers routine household purchases that people keep buying even in a downturn, which cushions the group against recessions. The exception is infant nutrition, where demand tracks birth rates rather than the economy: Mead Johnson's growth in 2025 came mainly from price and mix rather than more babies being fed, since volumes actually declined.
Os argumentos a favor
Buyers argue that the 2025 turnaround is real — Core Reckitt like-for-like revenue grew 5.2%, led by double-digit growth in Emerging Markets — and that the Essential Home sale sharpens the portfolio around higher-margin health and hygiene brands while returning capital to shareholders through a special dividend.
Os argumentos contra
Sellers point to a stalled Europe (like-for-like revenue down 4.5% in 2025) and soft North America, and worry that hundreds of pending U.S. lawsuits alleging Enfamil premature-infant formula causes necrotizing enterocolitis — with a jury already awarding $60 million in one case — could impose costs and reputational damage far beyond what today's price assumes.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$13.35B
Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação
Resultado Líquido
$2.81B
Últimos 12 meses até o último trimestre divulgado — estimativa a partir de métricas por ação
Fluxo de Caixa Livre
$3.09B
Capital Próprio Total
$5.67B
Passivo Total
$10.25B
Rácio de Liquidez
0.59
Cobertura de Juros
-
Dívida/EBITDA
2.86
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$2156.36
Preço Atual
$5150.00
Margem de Segurança
-138.8%
Intervalo de Valor Justo
$1401.63 - $2911.08
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
1169.99
ROE
48.0%
Rácio P/B
580.17
P/FCF
1049.76
Margem Bruta
59.6%
ROIC
12.3%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
12.3%
WACC
8.5%
ROIC − WACC
+3.8 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critérios de Análise Fundamental
Aprovado (10)
- ROIC 12.3%
- Gross Margin 59.6%
- Debt/Equity ratio
- Operating Margin 28.5%
- Positive Free Cash Flow
- Debt/EBITDA
- ROE 42.9%
- Analyst Consensus 76% Buy
- PEG Ratio 0.47
- Net Margin Trend 22.4% vs 10.1%
Reprovado (11)
- Price CAGR -3.27%
- P/FCF 1049.76
- P/B Ratio 580.17
- CapEx intensity
- Current Ratio
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 0.3%
- Earnings Surprise avg 2.4%
- Earnings Quality (OCF/NI) 0.66
- Piotroski F-Score 1/9
Indisponível (6)
- EPS data insufficient
- Dividend Payout NaN%
- Interest Coverage
- Return on Tangible Assets
- Low reliance on intangibles
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Moderada: alguma diferença entre lucros e caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Kristoffer Loe Licht | CEO & Executive Director | 49 |
| Ms. Shannon Sue Eisenhardt | CFO & Executive Director | 51 |
| Mr. Nicholas James Ashworth C.F.A. | Senior Vice President of Investor Relations | - |
| Ms. Catheryn O'Rourke | Senior VP, General Counsel & Company Secretary | 52 |
| Ms. Sheila Redzepi | Chief Communications & Corporate Affairs Officer | 46 |
| Mr. Ranjay Radhakrishnan | Chief Human Resources Officer | 54 |
| Mr. Jerome Lemaire | President North America | 51 |
| Ms. Angela Naef Ph.D. | Chief Research & Development Officer | 49 |
| Ms. Susan Sholtis | President of Nutrition | 58 |
| Dr. Alessio Fasano M.D. | Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business | - |
Risco de Auditoria
4
Risco do Conselho
2
Risco de Remuneração
3
Risco dos Direitos dos Acionistas
1
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for RBGPF, sourced from Markets Gazette.